Thirty unselected patients with chronic granulocytic leukaemia (CGL), age range 22-59 years, were treated with intensive chemotherapy and G-CSF to mobilize peripheral blood progenitor cells (PBPC). Chemotherapy was well tolerated and PBPC were collected by leukapheresis early during white cell recovery. PBPC collections considered adequate for engraftment were collected in 21 patients. Cytogenetic analysis of all collections in these patients showed Ͼ75% Ph negativity (range 79-100%) in 10. Successful collections, ie those Ͼ75% Ph negative and with total cell count of Ͼ1 × 10 6 CD34+ve cells/kg or Ͼ20 × 10 4 CFU-GM/kg were further analysed by Southern blot or RT-PCR. All samples were positive for the bcr/abl transcript. Patients with a low Sokal score (Ͻ0.8) were more likely to achieve a successful collection. In contrast, there was no association between transcript expression and likelihood of successful collection. We have confirmed that it is possible to mobilize and collect Ph-negative enriched PBPC in unselected patients with CGL. This procedure is more likely to be successful earlier rather than later in the course of the disease. Whether such collections will give an advantage over unmanipulated autologous bone marrow transplantation in CGL requires further study, but our experience suggests that suitable material for autologous rescue can be obtained from approximately one third of eligible, unselected young patients.
Introduction
Chronic granulocytic leukaemia (CGL) is a malignant disease of the haemopoietic stem cell whose natural history and cytogenetic features are well described. 1 The only form of therapy currently offering a cure in CGL is allogeneic transplantation from an HLA-matched related or unrelated donor. 2, 3 The availability of a suitable donor and the toxicity of the procedure, particularly with increasing age, limit its application to less than 40% of patients. Within the Northern Region of England only 20% of eligible patients will have a suitable HLA-matched sibling donor. 4 For those patients not suitable for allogeneic transplantation, treatment with alpha-interferon has been shown to prolong survival when compared to conventional chemotherapy, and where a major cytogenetic response occurs survival appears to be significantly prolonged. [5] [6] [7] Unfortunately only a minority of patients demonstrate this 'best' response to treatment, and even for these the possibility of cure is likely to remain elusive. There remains therefore, a significant proportion of patients for whom alternative treatments must be investigated.
A number of investigators have shown that normal haemopoiesis persists in patients with CGL, at least early in the course of the disease. 8, 9 Autologous transplantation using bone marrow collected in chronic phase CGL restores haemopoiesis, and is attractively free from many of the more toxic side-effects of allogeneic transplantation. In some patients reengrafted bone marrow has been Ph negative. 10, 11 There is now a suggestion that autologous transplantation also improves survival in CGL. 12 Recently some centres have reported attempts to improve the quality of autologous material available for transplant by eliminating or reducing the size of the Ph-positive clone. 9, [13] [14] [15] [16] [17] In some patients it is possible to collect autologous haemopoietic peripheral blood progenitor cells (PBPC) of which only a minority may be Ph positive. A number of transplants have now been performed using these cells with encouraging results. These procedures have not been without their mortality and morbidity, however, and the indications for and timing of such transplants need clarification by further studies.
Following on from these reports a pilot study was undertaken in the Northern Region of England. Our aim was to assess the feasibility of collecting Ph-negative enriched PBPC in all newly diagnosed patients with CGL under the age of 60. It seemed likely that the collection of such cells would be most successful if performed as soon after diagnosis as possible, when normal haemopoiesis persists in the bone marrow.
Patients and methods

Patients and mobilization therapy
The Northern Health Region of England serves a population of 3.08 million. Total registration of all new cases of CGL has been in place since January 1988. A median of 25 new cases present per annum (range [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . 4 From January 1994 a programme of early intervention for patients under 60 years of age was begun with the cooperation of all 25 regional haematologists. In the 40 months to April 1997 97 new patients were registered; 53 were aged under 60. Eight patients were aged 55-60 and their referral to the programme was at the discretion of the local haematologist depending on coexisting medical problems. Two patients in this age group were referred. Thus 47 patients were potentially eligible for the stem cell harvesting programme.
Six of the 47 patients have an HLA-matched sibling and have received or await an allotransplant, two were referred for consideration of matched unrelated donor transplant and one died within 2 weeks of diagnosis. Therefore 38 patients were potentially eligible for high-dose chemotherapy and PBPC harvest.
Two patients were unable to give informed consent, two could not be referred for contracting reasons, two were not referred and one was in blast crisis when admitted for highdose chemotherapy. All patients were treated initially with hydroxyurea to establish a stable chronic phase. Chronic phase bone marrow was harvested and cryopreserved as a back-up in case of later clinical need. Mobilizing chemotherapy consisted of daunorubicin 100 mg/m 2 / day 1, vincristine 2 mg day 1, cytosine arabinoside 100 mg/m 2 twice a day days 1-7, all intravenously, and prednisolone 50 mg twice a day days 1-5 orally. In two patients (Nos 2 and 3) the dose of daunorubicin was split and given over 2 days. Three patients failed to achieve an adequate white cell count nadir with this regimen and a second mobilization with high-dose hydroxyurea 3.5 g/m 2 for 7 days was performed. 19 Patient No. 30 was mobilized at the first attempt with hydroxyurea because of a poor cardiac assessment.
Patients 19-30 were given ciprofloxacin 750 mg twice a day and fluconazole 50 mg once a day for 1 week from white 
Statistical analysis
The Mann-Whitney test was used to correlate Sokal score with likelihood of achieving a successful harvest, and the Fisher's exact test to analyse the breakpoint data.
Leukapheresis
Leukapheresis started when the white cell count was Ͼ0.8 × 10 9 /l and rising, and continued until a target of Ͼ1 × 10 8 mononuclear cells/kg (patients 1 and 2) or Ͼ1 × 10 6
CD34+ve cells/kg (patients 3-30) patient weight had been collected. Leukapheresis was performed with a MCS 3p cell separator (Haemonetics, Leeds, UK) using the PBPC collection programme. Each leukapheresis product was tested for both engraftment potential and Ph-positive cell contamination. Engraftment potential was assessed by estimating the progenitor cell content of the product by colony assays for haemopoiesis (granulocyte-macrophage colony-forming unit (CFU-GM) assay), and CD34 + cell estimation by flow cytometry using a modified Sutherland method. 20 The minimum criteria for adequate engraftment are considered to be Ͼ20 × 10 4 /kg CFU-GM and Ͼ1 × 10 6 /kg CD34 + cells. 21 Malignant cell contamination was assessed by both standard cytogenetic analysis and molecular techniques. For cytogenetics a target of 30 metaphases was required for accurate results. The assay was considered a failure if fewer than 10 metaphases were seen, and results of 10-30 metaphases are only quoted where they are in keeping with the results of harvest days where у30 metaphases were counted. The cytogenetic results were confirmed by Southern blot examination using the probes pBCR 22 or Transprobe (Oncogene Science, Cambridge, UK) derived from the major breakpoint cluster region. In cases where the product showed no evidence of malignant cell contamination by these methods, minimal residual disease was assessed by one-and two-round PCR amplification of the bcr/abl transcripts. 23, 24 The site of the breakpoint and RNA transcript produced was also assessed in all patients.
The harvest was considered successful if the target number of stem cells was collected and all products were Ͼ75% Ph negative.
Post-PBSC harvest treatment
A bone marrow investigation for cytogenetic examination was performed following completion of stem cell collection and all patients have subsequently been commenced on interferon. Those who have a successful collection and fail to respond to interferon will be considered for autologous transplantation.
Results
Thirty-nine patients in the Northern Region were of a suitable age for an intensive approach and were without an allograft donor. Thirty-one have been accepted on to the programme (79% of the available patient population). Thirty patients have so far completed the mobilization procedure. Chemotherapy was well tolerated and administered where possible as an outpatient after day 2. All but three of the first 18 patients developed neutropenic fevers requiring admission for antibiotic therapy. All 18 required platelet support. Of patients 19-30 given ciprofloxacin and fluconazole prophylaxis only one required admission for fever. Seven required platelet support. The median time from start of chemotherapy to the start of PBPC collection was 19 days (range 16-28 days). The timing of PBPC collections was relatively predictable, with 25 of 30 patients beginning between days 16 and 21 after chemotherapy. Interestingly, none of the five patients beginning leukapheresis after this period achieved good Ph-negative PBPC collections. Table 2 shows the results of the assessment of engraftment potential and malignant cell contamination of the PBPC harvests. In 21 of the 30 patients sufficient PBPC were collected for engraftment (Ͼ1 × 10 6 /kg CD34 + cells or Ͼ20 × 10 4 /kg CFU-GM). In 10 of these patients all PBPC collections showed Ͻ25% Ph-positive metaphases. Overall, harvests highly enriched for Ph-negative cells (Ͻ25% Ph positive) and with adequate engraftment potential were achieved in 10 of 30 patients (33%).
There was a significant (P = 0.0107) association between Sokal score and achievement of a successful harvest ( Figure 1) ; 7/14 patients with a low Sokal score (Ͻ0.8), 3/10 with an intermediate score (0.8-1.2) and 0/6 with a high score (Ͼ1.2) satisfied our criteria for successful collections.
Cytogenetic results have been confirmed at a molecular 
Figure 1
Correlation between Sokal score and harvest quality. level with Southern blot for the bcr rearrangement (data not shown). In the 10 patients with successful harvests and Ͼ75% Ph-negative collections by cytogenetic analysis both SB and PCR for bcr/abl were performed. All harvests were positive. Two-round PCR was required to detect low levels of malignant cells in a proportion of the harvests of three patients (Nos 1, 17 and 18; Table 3 ). The type of bcr/abl transcript expressed by the malignant cells was further investigated (Table 4) . Eight of 30 patients Table 4 Correlation between bcr/abl transcript and outcome expressed b2a2, or in one case b2a3, type transcripts and four of these (50%) yielded adequate Ph-negative PBPC harvests. The remaining patients expressed b3a2 transcripts either alone or in conjunction with b2a2, and only six of 22 (27%) yielded transplantable harvests. This difference is not statistically significant by Fisher's exact test. The incidence of patients showing the b2a2 or b2a3 transcript compared to b3a2 in this study (27: 73%) is similar to that found in the CGL population in our region (40: 60%, unpublished observations) and that found by other investigators. 25 All patients have started treatment with ␣-interferon following their PBPC mobilization and collection. Only two of 22 patients have achieved a major cytogenetic response. The duration of follow-up for the remaining patients is too short to assess their interferon response (Ͻ6 months).
Patient
Discussion
This demographically based pilot study confirms that it is possible to harvest peripheral blood stem cells highly enriched with Ph-negative cells and containing sufficient haemopoietic progenitors for transplantation in unselected patients with CGL. In some cases the minimal residual disease was at such a low level that it could only be detected by RT-PCR methods. This has been achieved using a regimen causing no mortality and acceptable morbidity. The ability to mobilize adequate numbers of haemopoietic progenitor cells for engraftment appears to be significantly associated with the patients' Sokal score at diagnosis confirming the observation by Hughes et al 26 who failed to achieve a successful harvest in any patient with a Sokal score Ͼ1.0. In contrast, Carella et al 27 using a more intensive mobilising regimen (idarubicin, cytosine arabinoside and etoposide (ICE)) found no association between achievement of a successful harvest and Sokal score at diagnosis.
The position of the breakpoint and RNA transcript, and their association with survival 28 and response to interferon 25, 29 have been the subject of considerable debate. To date, a consistent association has not been shown. Our results also fail to demonstrate any association between position of breakpoint and probability of achieving a successful harvest.
Compared to the results reported by some other investigators 13 negative PBPC collections. A number of patients have collections that are 100% Ph-negative on 1 or 2 days of their harvest, but show the occasional Ph-positive metaphase on the other days. The potential clinical importance of this low level of contamination is difficult to judge. The difference in results between this and other studies may be due to differences in the mobilization chemotherapy used, with less effective eradication of malignant cells, but clearly other variables may be involved; in particular the means of assessing malignant cell contamination.
There are intrinsic inaccuracies in assessing malignant cell contamination by cytogenetic examination alone; only cells in metaphase can be assessed, and these may not accurately reflect the whole PBPC population. In this study the cytogenetic asssessment was based on the analysis of 30 metaphases. Analysis of 30 metaphases cannot exclude a clone of up to 10% Ph-positive cells at the 95% confidence limit. 32 Other studies 13, 26, 31 are based on the analysis of 20 metaphases (clones of up to 14% Ph-positive cells cannot be excluded). Such variation in the number of metaphases examined could go some way towards explaining the apparently lower levels of completely Ph-negative collections in this study. In order to improve accuracy we have also tested the PBPC harvests using Southern blot and RT-PCR techniques. In common with Chalmers et al 31 and Johnson et al 19 not one of the PBPC collections in this study was bcr/abl negative by RT-PCR methods although in three patients only low levels of malignant cell contamination could be detected by tworound PCR.
The assessment of Ph-positive contamination of the whole PBPC collection may be less important than the molecular status of the primitive haemopoietic stem cells that divide and differentiate to reconstitute the bone marrow. Unfortunately problems identifying these cells makes more specific analysis difficult but not impossible using interphase fluorescence in situ hybridization (I-FISH) or RT-PCR technniques on single CFU-GM colonies. 33 The relevance of low levels of malignant cell contamination will only become apparent when more mature transplant data exist for these patients.
In a recently published update by Carella et al 30 two of 16 patients treated early and prior to the start of interferon produced Ph-negative harvests capable of engraftment, compared with eight of 16 patients treated early but after interferon therapy, and only four of 17 patients treated longer than 1 year from diagnosis. The conclusion of the study was that the procedure was more successful and less toxic if performed early in the course of the disease and prior to treatment with ␣-interferon. The results shown here, and those reported by other investigators 15, 31 support that hypothesis although greater patient numbers are required to confirm this.
The optimal mobilizing schedule remains to be defined. In our study a schedule was chosen that was expected, and proved, to cause little morbidity. Johnson et al 19 have used high-dose hydroxyurea and GCSF in a mixed cohort of 10 patients with some success. Four of the patients mobilized had collections that were Ph-negative cytogenetically but had cells positive for t(9;22) using FISH. All patients were positive for bcr/abl using RT-PCR. The true potential of this regimen in larger numbers of newly diagnosed patients remains to be evaluated. Hughes et al 26 have mobilized 75-100% Ph-negative cells in at least one leukapheresis in seven of 21 evaluable patients using high-dose cyclophosphamide and GCSF. This regimen caused no mortality and tolerable morbidity. Carella et al 27 have shown that the intensive ICE regimen, which has considerable toxicity in patients with more advanced disease, is well tolerated in the newly diagnosed patient and may produce a higher yield of Ph-negative PBPC. In 12 of 17 patients (71%) mobilized with this regimen the leukapheresis product was entirely Ph negative (29-232 metaphases examined). Chalmers et al 31 observed good responses using the ICE regimen but cautioned that results had to be balanced against high toxicity. This group is now using a lower dose idarubicinbased regimen. For patients previously treated with interferon Carella et al 34 have modified their treatment to mini-ICE without seeing a reduction in cytogenetic response or progenitor yield, but with a reduction in non-haematological toxicity.
How then should a newly diagnosed patient with CGL and no allogeneic donor be managed? We propose that all patients should be offered the best chance of obtaining a successful PBPC harvest as soon after diagnosis as practically possible. This would be followed in all patients by a trial of interferon, with those responding continuing the drug and those not being considered for autotransplantation.
The role of autotransplantation in CGL is currently being evaluated but no randomized trial has yet been completed. Some studies suggest a survival advantage for autologous transplantation in CGL, but the number of patients reported remains small and the survival data relatively immature. Furthermore, while a theoretical advantage exists for the use of Ph-negative PBPC over unmanipulated chronic phase bone marrow, there are no outcome data yet to support this view. We have also shown that a low Sokal score at diagnosis was closely associated with successful harvests. It will be interesting to note in future studies of autologous transplantation whether Sokal scores and/or 'successsful' harvests are both independent predictors of outcome.
If patients are to undergo PBPC mobilization early in the course of their disease then that procedure must be safe. Early mortality is unacceptable. In this, the first demographically based study of its kind, we have shown such an approach is possible and can be organized on a regional basis to include the great majority (79%) of eligible patients. The demographic data we present also confirm that the workload is manageable. With appropriate organisation and communication it should be possible for other groups of haematologists to offer PBPC harvests to most eligible patients from a similar-sized population, rather than continuing to carry out studies on highly selected groups of patients. Early PBPC harvesting may increase the number of patients from whom a cell product highly enriched for Ph-negative cells can be obtained. Whether the subsequent transplantation of such harvest products will offer a viable treatment alternative for patients failing interferon therapy remains to be seen. The results so far suggest further investigation is warranted, and that existing studies should be continued.
